Search
Now showing items 21-30 of 34
Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
(
Massachusetts Medical Society
, 2022 , Article)
The BNT162b2 vaccine against coronavirus disease 2019 (Covid-19) has been authorized for use in children 5 to 11 years of age and adolescents 12 to 17 years of age but in different antigen doses. We assessed the real-world ...
Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
(
Oxford University Press
, 2022 , Article)
The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study
(
Elsevier
, 2022 , Article)
BackgroundUnderstanding protection conferred by natural SARS-CoV-2 infection versus COVID-19 vaccination is important for informing vaccine mandate decisions. We compared protection conferred by natural infection versus ...
Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses.
(
Oxford University Press
, 2021 , Article)
Strategies for rolling out vaccination against Coronavirus Disease 2019 (Covid-19) varied across countries. A key question is whether delaying administration of the second vaccine dose to vaccinate the largest number of ...
Severity, Criticality, and Fatality of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta Variant
(
Oxford Academic
, 2021 , Article)
Beta (B.1.351) variant COVID-19 disease was investigated in Qatar. Compared to Alpha (B.1.1.7) variant, odds of progressing to severe disease were 1.24-fold (95% CI: 1.11-1.39) higher for Beta. Odds of progressing to ...
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study
(
Elsevier
, 2023 , Article)
BackgroundProtection against SARS-CoV-2 symptomatic infection and severe COVID-19 of previous infection, mRNA two-dose vaccination, mRNA three-dose vaccination, and hybrid immunity of previous infection and vaccination ...
Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar
(
Springer
, 2023 , Article)
Background: Limited data exists on herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections in migrant populations. This study investigated HSV-1 and HSV-2 seroprevalences and associations among craft and manual ...
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
(2023 , Article)
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ...
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study
(
Elsevier
, 2023 , Article)
BackgroundWaning of natural infection protection and vaccine protection highlight the need to evaluate changes in population immunity over time. Population immunity of previous SARS-CoV-2 infection or of COVID-19 vaccination ...
Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study
(
Elsevier
, 2023 , Article)
ObjectivesWe assessed short-, medium-, and long-term all-cause mortality risks after a primary SARS-CoV-2 infection. MethodsA national, matched, retrospective cohort study was conducted in Qatar to assess risk of all-cause ...